Drugs / AZD7268
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01116011 | Apr → Jul 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00912353 | May → Oct 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00861718 | Apr → Oct 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00796965 | Dec 2008 → Mar 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01020799 | Nov 2009 → Apr 2010 | major depressive disorder | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7268 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01020799 ↗ |
| Known as | AZ-12488024 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1946618 ↗ |
| Action | Activate | “Delta opioid receptor agonist” CHEMBL1946618 ↗ |
| Modality | Small molecule | — CHEMBL1946618 ↗ |
| Route | Oral | “Solution/Capsule, Oral, once daily” NCT00796965 ↗ |
| Target | OPRD1 | “Delta opioid receptor agonist” CHEMBL1946618 ↗ |